$DGX

Davis J. E. sold $1.9M of DGX

Davis J. E. (CEO and President) sold 10,000 shares of QUEST DIAGNOSTICS INC (DGX) at $194.14 ($1.94M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Davis J. E.
Published Jun 2, 2026, 10:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 10:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DGX
Neutral
medium confidence
Mentioned
$DGX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DGXNeutralLow
01

Why it matters

The disclosure may influence short-term sentiment among traders who track insider flows, but the 10b5-1 designation generally lowers the probability of a fundamental read-through.

02

Market read

A disclosed insider sale in DGX; likely more relevant for sentiment/positioning than for fundamentals.

03

What to watch

The filing does not indicate whether additional tranches remain under the same 10b5-1 plan, nor does it provide context on the executive’s broader compensation/hedging activity.

Relevance 6/10Novelty 6/10Timing: Filed after-hours on 2026-06-02; reflects sale executed 2026-06-01.

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the CEO/President under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$DGXNeutralMedium confidence
Context

Quest Diagnostics CEO and President Davis J. E. sold 10,000 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is more likely short-term and sentiment-driven.

Evidence & confidence

The filing is a routine insider disclosure and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary sales.

Market effects

Minimal; this is company-specific insider activity with no stated operational/regulatory catalyst.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can be purely mechanical; the sale may not reflect bearish fundamentals and could be offset by other insider buys or institutional activity not shown here.

Key entities

  • Quest Diagnostics Inc

    DGX, the company whose shares were sold by its CEO/President.

  • Davis J. E.

    CEO and President who executed the sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DGXMed

New York State Data Exposed Following Quest Diagnostic Breach

Quest Diagnostics disclosed a data breach in its Quanum Lab Services Manager system, exposing patient records, including names, Social Security numbers, and medical information. The breach was contained, but the exact number of affected individuals is still under investigation. Quest will notify impacted patients and offer identity theft monitoring services. The company serves 1 in 3 American adults annually.

$DGXMed

Quest Diagnostics says unauthorized access to lab-ordering system exposed patient records

Quest Diagnostics reported unauthorized access to its Quanum Lab Services Manager system, exposing patient records. The breach was discovered on Oct. 21, 2026, and disclosed the next day. The company is investigating with outside experts and has notified law enforcement. No disruption to customer operations was reported, and no threat group has claimed responsibility. Quest has temporarily paused access to affected systems and recommended alternative methods for orders and results.

$DGXLow

Medical Testing Giant Quest Diagnostics Confirms Massive Security Breach Exposing Sensitive Patient Records Amid a Coordinated Global Hacking Surge

Quest Diagnostics confirmed a security breach exposing patient records via its Quanum Lab Services Manager system. The breach, discovered on October 21, impacted protected health information and personal data. The company has taken steps to contain the breach, but the full extent of the damage is still under investigation. This incident is part of a broader surge in global cyberattacks, including a critical flaw in the PHP programming language.

$DGXMedAI 8/10

Quest Diagnostics Q3 2026 Revenue Rises to $3.1B, Diluted EPS Up to $2.78

Quest Diagnostics reported Q3 2026 revenue of $3.1B, up 10% YoY, with diluted EPS rising to $2.78. Operating income increased to $479M. Year-to-date revenue reached $9.035B, with net income attributable to Quest at $884M. The company maintained strong cash flow and returned capital through buybacks and dividends, but noted rising operating costs and debt.